HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data

被引:14
作者
Tarasova, Olga [1 ]
Poroikov, Vladimir [1 ]
机构
[1] Inst Biomed Chem, 10 Bldg 8,Pogodinskaya St, Moscow 119121, Russia
来源
MOLECULES | 2018年 / 23卷 / 04期
基金
俄罗斯科学基金会;
关键词
HIV; reverse transcriptase; resistance; computational prediction; amino acid sequences; nucleotide sequences; open data; PHENOTYPIC DRUG-RESISTANCE; INTERPRETATION ALGORITHM; ANTIRETROVIRAL TREATMENT; COMPUTATIONAL MODELS; PHENOSENSE ASSAYS; TYPE-1; MUTATIONS; PROTEASE; SUSCEPTIBILITY; ANTIVIROGRAM;
D O I
10.3390/molecules23040956
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Research and development of new antiretroviral agents are in great demand due to issues with safety and efficacy of the antiretroviral drugs. HIV reverse transcriptase (RT) is an important target for HIV treatment. RT inhibitors targeting early stages of the virus-host interaction are of great interest for researchers. There are a lot of clinical and biochemical data on relationships between the occurring of the single point mutations and their combinations in the pol gene of HIV and resistance of the particular variants of HIV to nucleoside and non-nucleoside reverse transcriptase inhibitors. The experimental data stored in the databases of HIV sequences can be used for development of methods that are able to predict HIV resistance based on amino acid or nucleotide sequences. The data on HIV sequences resistance can be further used for (1) development of new antiretroviral agents with high potential for HIV inhibition and elimination and (2) optimization of antiretroviral therapy. In our communication, we focus on the data on the RT sequences and HIV resistance, which are available on the Internet. The experimental methods, which are applied to produce the data on HIV-1 resistance, the known data on their concordance, are also discussed.
引用
收藏
页数:20
相关论文
共 84 条
  • [11] Genetic Variability of HIV-1 for Drug Resistance Assay Development
    Clutter, Dana S.
    Rojas Sanchez, Patricia
    Rhee, Soo-Yon
    Shafer, Robert W.
    [J]. VIRUSES-BASEL, 2016, 8 (02):
  • [12] De Luca A., 2006, Antiretroviral resistance in clinical practice
  • [13] Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations
    Demeter, L
    Haubrich, R
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 : S3 - S9
  • [14] Demeter LM, 1998, J VIROL METHODS, V75, P93, DOI 10.1016/S0166-0934(98)00100-1
  • [15] Structural determinants and molecular mechanisms for the resistance of HIV-1 RT to nucleoside analogues
    Deval, J
    Courcambeck, J
    Selmi, B
    Boretto, J
    Canard, B
    [J]. CURRENT DRUG METABOLISM, 2004, 5 (04) : 305 - 316
  • [16] Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations
    Deval, J
    White, KL
    Miller, MD
    Parkin, NT
    Courcambeck, J
    Halfon, P
    Selmi, B
    Boretto, J
    Canard, B
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (01) : 509 - 516
  • [17] Molecular Aspects of the RT/drug Interactions. Perspective of Dual Inhibitors
    Distinto, Simona
    Maccioni, Elias
    Meleddu, Rita
    Corona, Angela
    Alcaro, Stefano
    Tramontano, Enzo
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (10) : 1850 - 1859
  • [18] Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors
    Doyon, L
    Payant, C
    Brakier-Gingras, L
    Lamarre, D
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (07) : 6146 - 6150
  • [19] Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial
    Durant, J
    Clevenbergh, P
    Halfon, P
    Delgiudice, P
    Porsin, S
    Simonet, P
    Montagne, N
    Boucher, CAB
    Schapiro, JM
    Dellamonica, P
    [J]. LANCET, 1999, 353 (9171) : 2195 - 2199
  • [20] Structure-based Design of Conformationally Flexible Reverse Transcriptase Inhibitors to Combat Resistant HIV
    Hao, Ge-Fei
    Yang, Sheng-Gang
    Yang, Guang-Fu
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (05) : 725 - 739